INNVInnovage Holding Corp.
The Read
6% decline after Q3 2026 earnings missed profitability expectations despite revenue beats.
The schedule
- Tue20Oct
Evaluation of ongoing operational audits and potential sanctions from state and federal agencies.
- Thu10Dec
Review of the Annual Enrollment Period results and impact on forward revenue visibility.
- Wed20Jan
Inauguration and initial executive orders impacting Medicare/Medicaid and PACE program funding.
- Tue4May
Check on MLR stabilization and cash flow following the winter utilization season.
- Tue10Aug
First look into fiscal 2027 operational scaling and capital expenditures.
Past
- Fri7Aug
Actual outcome: Bear · $10.61 at outcome
InnovAge reported fiscal Q4 earnings that matched analyst estimates with an EPS of -$0.22. Despite meeting bottom-line expectations, the stock fell 5.1% by the outcome date, including a sharp 6.4% drop on August 11. The market reacted negatively as the results and FY27 guidance failed to provide the necessary reassurance regarding the company's path to profitability.
Market reaction to the upcoming earnings and forward guidance, focusing on the path to profitability.
- Wed1Jul
Actual outcome: Bull · $11.52 at outcome
InnovAge announced new PACE center openings and regional expansions, successfully executing on its strategic growth initiatives. Although the stock consolidated slightly by 1.6% following the announcement, it remained significantly above the $8.60 bull target, closing at $11.52. The market maintained its bullish outlook as the expanded footprint signals increased patient capacity and long-term revenue growth potential.
InnovAge's expected announcement of new PACE center openings or regional expansions.
- Tue5May
Actual outcome: Bear · $7.55 at outcome
InnovAge reported a fiscal Q3 loss of $0.22 per share, missing consensus estimates and marking a relapse into unprofitability, even though revenue beat expectations. This return to a quarterly loss failed the critical profitability test that investors were focused on, raising concerns about seasonal cost pressures and margin erosion, which caused the stock to drift lower.
Q3 2026 earnings is the next major checkpoint on whether InnovAge can sustain Q2’s return to profitability, keep medical loss ratios under control, and grow PACE enrollment without eroding margins. At a base price of $8.35, a clean quarter with another quarter of positive EPS and stable MLR could justify a move toward $10.30, while a relapse into losses or higher care costs could see the shares retrace toward $10.30.
- Wed1Apr
Actual outcome: Mixed · $8.15 at outcome
No specific updates regarding the securities fraud class action settlement were released around the event date. Instead, the stock's movement was primarily driven by an analyst upgrade that sparked a brief rally, leaving shares relatively flat overall and trading between the bull and bear targets.
Legal resolution regarding past disclosure failures during the CMS sanction period.
- Tue3Feb
Actual outcome: Bull · $8.36 at outcome
InnovAge reported fiscal Q2 2026 EPS of $0.078, exactly meeting analyst estimates. The stock surged 47.7% well past the bull target, indicating that the underlying details of the report—specifically the highly anticipated enrollment and Medical Loss Ratio (MLR) metrics—strongly satisfied investor expectations. Additionally, positive visibility from the company's active engagement with Colorado state lawmakers to protect PACE funding helped bolster confidence in its regulatory and operational environment.
Report for period ending 2025-12-31. Investors will focus on sustained enrollment growth in post-sanction markets (Colorado) and Medical Loss Ratio (MLR) stability, a key metric for profitability path.
